Oil & Gas Firm's Q2/18 Shows Production Upside, 'Portfolio Cleanup,' Strong Cash Flow
Source: Streetwise Reports
August 13, 2018 (Investorideas.com Newswire) A Raymond James report reviewed the company's most recent financial and production numbers.
In an August 2 research note, analyst Pavel Molchanov with Raymond James reported that against a backdrop of increased production and high cash flow in Q2/18, Marathon Oil Corp.'s (MRO:NYSE) earnings per share (EPS) was a miss and the company still has not reinstated a share buyback.
As for overall production, in Q2/18, the first quarter following the sale of its Libya asset, it was 419 thousand barrels of oil equivalent per day (419 Mboe/d), higher than Raymond James' expected 411 Mboe/d and at the upper end of the Marathon's 2018 guidance range of 395–415 Mboe/d, relayed Molchanov.
In terms of U.S. production, it grew 5% in Q2/18 to 298 Mboe/d. The Bakken, up 11% to 82 Mboe/d, saw the greatest jump. SCOOP/STACK production increased 7% to 80 Mboe/d. The Permian was up 7% and the Eagle Ford, 2%. International volumes increased 6% during the quarter. For Q3/18, production is expected to be between 395 and 415 Mboe, a 3% quarter-over-quarter drop.
Molchanov indicated that for the second time, Marathon Oil increased its full year 2018 production, this time to 400–415 MBoe/d. This is despite the sale in July of three assets cumulatively producing about 5 Mboe/d: nonoperated Gunflint and Troika in the Gulf of Mexico and a CO2 Waterflood in West Texas. The company also is divesting of its nonoperated Sarsang and Atrush blocks, its only Kurdistan assets.
Marathon Oil's Q2/18 adjusted EPS was $0.15, below Raymond James' estimate of $0.26 and consensus' forecast of $0.20. Molchanov explained, "Realized liquids pricing drove the miss versus our model, a common enough story this cycle amid the relentless volatility in crude price spreads."
The company's Q2/18 operating cash flow was $638 million ($638M), which "more than covered capital spending," wrote Molchanov. This compares to Q1/1 cash flow of $638M. In 2018,"we project $1.1 billion ($1.1B) of free cash flow, the highest since 2011, before the refining spinoff."
At Q2/18E, Marathon's cash balance was $1.7B, making it "an excellent candidate to reinstate share buyback, last seen in H1/14, and following such peers as Anadarko, Cabot, Devon and Hess. Alas, management is not pulling the trigger yet, but we haven't given up hope!"
About Marathon Oil in general, Molchanov highlighted that it differentiates itself by having a significant presence in all four of the U.S. liquids-rich plays: the Eagle Ford, Bakken, Permian and SCOOP/STACK, the latter being "our favorite part of the story and with the most room to surprise."
Raymond James has a Strong Buy rating and a $25 per share target price on Marathon Oil, whose stock is trading currently at around $20.09 per share. "The stock offers some of the highest leverage among large caps to our forecast for oil prices reaching cyclical highs over the medium term," added Molchanov.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Raymond James, Marathon Oil Corp., August 2, 2018
Analyst Compensation: Equity research analysts and associates at Raymond James are compensated on a salary and bonus system. Several factors enter into the compensation determination for an analyst, including i) research quality and overall productivity, including success in rating stocks on an absolute basis and relative to the local exchange composite Index and/or a sector index, ii) recognition from institutional investors, iii) support effectiveness to the institutional and retail sales forces and traders, iv) commissions generated in stocks under coverage that are attributable to the analyst's efforts, v) net revenues of the overall Equity Capital Markets Group, and vi) compensation levels for analysts at competing investment dealers.
The views expressed in this report accurately reflect the personal views of the analyst(s) covering the subject securities. No part of said person's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. In addition, said analyst has not received compensation from any subject company in the last 12 months.
RAYMOND JAMES RELATIONSHIP DISCLOSURES
Raymond James & Associates makes a market in shares of MRO.
Additional Risk and Disclosure information, as well as more information on the Raymond James rating system and suitability categories, is available here.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.